High rates of kidney impairment among older people (≥ 60 years) living with HIV on first-line antiretroviral therapy at screening for a clinical trial in Kenya
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0285787 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Jeremy Penner und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Epidemiological Modelling and Analysis, University of Nairobi, Nairobi, Kenya. Hauptthemen laut MEDLINE: HIV Infections, Anti-HIV Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Background
There is a paucity of data on kidney impairment among older people living with HIV (PLWH). We evaluated kidney function among PLWH age ≥ 60 years on first-line antiretroviral (ARV) therapy during screening for a clinical trial in Kenya.
Methods
The bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) Elderly Study is an open-label, randomized, active-controlled, non-inferiority trial conducted at two sites in Kenya. Potential participants were screened for study entry if they were at least 60 years old, had been on ARVs for at least 24 weeks and had no history of treatment failure. At screening, participants had samples collected for serum creatinine and estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration 2021 equation.
Results
Between January and April 2022, 714 participants were screened and had creatinine measured. All participants were black, 54.1% were female and the median age was 64 years (range 60 to 87 years). Most participants (666 [93.3%]) were on tenofovir disoproxil fumarate-containing regimens, 711 (99.6%) were on dolutegravir-containing regimens, and only 2 (0.3%) were on a regimen with a ritonavir-boosted protease inhibitor. Most participants (686 [96.6%]) were virally suppressed. Treatment for comorbidities was common, with 175 (24.5%) on treatment for hypertension and 39 (5.5%) on treatment for diabetes mellitus. The median eGFR was 64.7 mL/min/1.73m 2 , and 289 (40.5%) participants had an eGFR < 60 mL/min/1.73m 2 . In multivariate analysis, factors associated with lower eGFR were female gender (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Epidemiological Modelling and Analysis, University of Nairobi, Nairobi, Kenya.
- Department of Family Practice, University of British Columbia, Vancouver, Canada.
- Department of Clinical Medicine and Therapeutics, University of Nairobi, Nairobi, Kenya.
- Kenyatta National Hospital, Nairobi, Kenya.
- London School of Hygiene and Tropical Medicine, London, United Kingdom.
- Department of Infectious Diseases/HIV Medicine, Royal Free London Foundation Trust, London, United Kingdom.
ORCID-Profile: Jeremy Penner
Förderung
- Gilead Sciences
Zitieren
APA
Penner, J., Ombajo, L. A., Otieno, D., Nkuranga, J., Mburu, M., Wahome, S., Pozniak, A., & Bhagani, S. (2023). High rates of kidney impairment among older people (≥ 60 years) living with HIV on first-line antiretroviral therapy at screening for a clinical trial in Kenya. PLOS ONE. https://doi.org/10.1371/journal.pone.0285787
Vancouver
Penner J, Ombajo LA, Otieno D, Nkuranga J, Mburu M, Wahome S, et al. High rates of kidney impairment among older people (≥ 60 years) living with HIV on first-line antiretroviral therapy at screening for a clinical trial in Kenya. PLOS ONE. 2023. doi:10.1371/journal.pone.0285787
BibTeX
@article{Penner2023,
author = {Penner, Jeremy and Ombajo, Loice Achieng and Otieno, Davies and Nkuranga, Joseph and Mburu, Margaret and Wahome, Simon and Pozniak, Anton and Bhagani, Sanjay},
title = {High rates of kidney impairment among older people (≥ 60 years) living with HIV on first-line antiretroviral therapy at screening for a clinical trial in Kenya},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0285787}
}
EUVIMED